| __timestamp | Geron Corporation | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8901000 | 16606000 |
| Thursday, January 1, 2015 | 9574000 | 21497000 |
| Friday, January 1, 2016 | 14695000 | 25462000 |
| Sunday, January 1, 2017 | 8437000 | 28195000 |
| Monday, January 1, 2018 | 12723000 | 33078000 |
| Tuesday, January 1, 2019 | 51272000 | 36523000 |
| Wednesday, January 1, 2020 | 50052000 | 41455000 |
| Friday, January 1, 2021 | 783000 | 74400000 |
| Saturday, January 1, 2022 | 868000 | 101582000 |
| Sunday, January 1, 2023 | 123740000 | 112903000 |
Infusing magic into the data realm
In the ever-evolving landscape of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Veracyte, Inc. and Geron Corporation from 2014 to 2023. Over this period, Veracyte, Inc. has shown a consistent upward trajectory, with costs peaking at approximately $113 million in 2023, marking a 580% increase from 2014. In contrast, Geron Corporation's cost of revenue fluctuated significantly, with a notable spike in 2023, reaching $124 million, a dramatic rise from previous years. This disparity highlights Veracyte's steady growth strategy compared to Geron's volatile expenditure pattern. Such insights are invaluable for those looking to understand the financial dynamics within the biotech sector, offering a window into how these companies manage their operational expenses over time.
Cost of Revenue: Key Insights for Johnson & Johnson and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Geron Corporation
Dr. Reddy's Laboratories Limited vs Geron Corporation: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Sarepta Therapeutics, Inc. and Geron Corporation
Analyzing Cost of Revenue: Lantheus Holdings, Inc. and Veracyte, Inc.
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs Geron Corporation
Comparing Cost of Revenue Efficiency: Amneal Pharmaceuticals, Inc. vs Veracyte, Inc.
Cost of Revenue Trends: Veracyte, Inc. vs Celldex Therapeutics, Inc.
Cost Insights: Breaking Down Veracyte, Inc. and Viridian Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Ligand Pharmaceuticals Incorporated vs Geron Corporation
Geron Corporation vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Geron Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored